1. Home
  2. UTF vs NAMS Comparison

UTF vs NAMS Comparison

Compare UTF & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Infrastructure Fund Inc

UTF

Cohen & Steers Infrastructure Fund Inc

HOLD

Current Price

$26.98

Market Cap

2.8B

Sector

Finance

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$38.50

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UTF
NAMS
Founded
N/A
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.3B
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
UTF
NAMS
Price
$26.98
$38.50
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$46.75
AVG Volume (30 Days)
295.3K
938.9K
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$17.96
Revenue Next Year
N/A
$540.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.42
$16.79
52 Week High
$27.35
$42.00

Technical Indicators

Market Signals
Indicator
UTF
NAMS
Relative Strength Index (RSI) 60.91 69.61
Support Level $26.65 $34.05
Resistance Level $27.17 $41.40
Average True Range (ATR) 0.34 2.20
MACD 0.04 0.62
Stochastic Oscillator 74.07 77.33

Price Performance

Historical Comparison
UTF
NAMS

About UTF Cohen & Steers Infrastructure Fund Inc

Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. Under normal market conditions, the fund invests the majority of its managed assets in securities issued by infrastructure companies, which consist of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: